^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Mesothelin-targeted antibody-drug conjugate

    Related drugs:
    Apply
    Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCI10208) (NCT03816358)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    12/09/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
    A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (NCT05804526)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    07/19/2023
    Primary completion :
    05/01/2025
    Completion :
    12/01/2025
    MSLN
    |
    MSLN positive
    |
    Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04175847)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    04/14/2020
    Primary completion :
    09/30/2024
    Completion :
    09/01/2025
    MSLN
    |
    misitatug blivedotin (RC88)
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (NCT05508334)
    Phase 1
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    01/30/2023
    Primary completion :
    06/30/2024
    Completion :
    12/30/2024
    MSLN
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (NCT03126630)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    10/04/2018
    Primary completion :
    07/08/2023
    Completion :
    09/21/2024
    PD-L1 • MSLN
    |
    PD-L1 expression • MSLN expression
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)
    Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) (NCT03102320)
    Phase 1b
    Bayer
    Completed
    Last update posted :
    06/30/2022
    Initiation :
    05/26/2017
    Primary completion :
    09/16/2020
    Completion :
    07/26/2021
    MSLN
    |
    MSLN expression
    |
    cisplatin • gemcitabine • anetumab ravtansine (BAY 94-9343)
    Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer (NCT03023722)
    Phase 2
    Yale University
    Completed
    Last update posted :
    10/28/2021
    Initiation :
    05/11/2017
    Primary completion :
    08/06/2019
    Completion :
    12/11/2019
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. (NCT01439152)
    Phase 1
    Bayer
    Completed
    Last update posted :
    07/09/2021
    Initiation :
    09/07/2011
    Primary completion :
    12/31/2016
    Completion :
    07/30/2019
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment (NCT02696642)
    Phase 1
    Bayer
    Completed
    Last update posted :
    07/09/2021
    Initiation :
    04/14/2016
    Primary completion :
    07/31/2018
    Completion :
    08/19/2019
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) (NCT02610140)
    Phase 2
    Bayer
    Completed
    Last update posted :
    11/04/2020
    Initiation :
    12/03/2015
    Primary completion :
    05/31/2017
    Completion :
    09/06/2019
    MSLN
    |
    MSLN expression
    |
    pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)
    Phase 1 Study of Mesothelin-ADC (NCT02884726)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    03/19/2020
    Initiation :
    10/14/2016
    Primary completion :
    09/06/2017
    Completion :
    09/06/2017
    MSLN
    |
    MSLN expression
    |
    BMS-986148
    Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors (NCT02639091)
    Phase 1
    Bayer
    Completed
    Last update posted :
    11/07/2019
    Initiation :
    02/03/2016
    Primary completion :
    05/23/2018
    Completion :
    10/17/2019
    EGFR • ALK
    |
    EGFR mutation • ALK translocation
    |
    cisplatin • pemetrexed • anetumab ravtansine (BAY 94-9343)
    PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (PAEMCMPAST) (NCT03615313)
    Phase 1/2
    Shanghai Cell Therapy Research Institute
    Unknown status
    Last update posted :
    08/03/2018
    Initiation :
    08/06/2018
    Primary completion :
    08/03/2020
    Completion :
    12/03/2020
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • fludarabine IV • BZD1901
    Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies (NCT02485119)
    Phase 1
    Bayer
    Completed
    Last update posted :
    06/04/2018
    Initiation :
    08/14/2015
    Primary completion :
    04/28/2017
    Completion :
    07/04/2017
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)